Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 224

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 224
---
-19,
Zika, and West Nile virus.

The Predecessor
is obligated to pay royalties at the rate of 3% of net sales. The Predecessor shall pay Yissum the following amounts in connection with
the achievement of the following milestones per each Product (each, a “Milestone”): (1) $150 upon first patient enrolled
in a Phase I Clinical Trial; (2) $300 upon first patient enrolled in a Phase II Clinical Trial; (3) $450 upon First patient enrolled
in a Phase III Clinical Trial and (4) $600 upon first commercial sale in either Europe or the US, the earlier to occur of the two.

NOTE 11 – SELECTED STATEMENTS OF OPERATIONS DATA

| a. | Research and development expenses: |

|                                |     | Successor 
 2024      | For the period commencing July 24, through 
                               December 31, |     | Predecessor 
 2024        | For the period commencing January 1, through 
                                     July 23, |     | 2023 | Year ended  December 31, |
|:-------------------------------|:----|:----------|-------------------------------------------:|:----|:------------|---------------------------------------------:|:----|:-----|-------------------------:|
| Subcontractors and consultants |     |           |                                        171 |     |             |                                          354 |     |      |                      490 |
| Share based payment            |     |           |                                        709 |     |             |                                          710 |     |      |                      205 |
| Payroll and related expenses   |     |           |                                        116 |     |             |                                           98 |     |      |                      151 |
|                                |     |           |                                        996 |     |             |                                        1,162 |     |      |                      846 |

| b. | General and administrative expenses: |

|                             |     | Successor 
 2024      | For the period commencing July 24, 
                            through 
                       December 31, |     | Predecessor 
 2024        | For the period commencing January 1, 
                              through 
                             July 23, |     | 2023 | Year ended  December 31, |
|:----------------------------|:----|:----------|-----------------------------------:|:----|:------------|-------------------------------------:|:----|:-----|-------------------------:|